Profile data is unavailable for this security.
About the company
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
- Revenue in USD (TTM)0.00
- Net income in USD-97.68m
- Incorporated2019
- Employees111.00
- LocationStructure Therapeutics Inc611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO 94080United StatesUSA
- Websitehttps://structuretx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.71bn | 226.00 | -- | 43.93 | -- | 29.43 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.73bn | 50.00 | -- | 4.95 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.83bn | 988.00 | -- | -- | -- | 3.05 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 2.87bn | 251.00 | -- | 3.23 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
Geron Corp | 520.00k | -201.40m | 2.89bn | 141.00 | -- | 8.31 | -- | 5,566.32 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
SpringWorks Therapeutics Inc | 26.45m | -339.07m | 2.90bn | 305.00 | -- | 5.11 | -- | 109.62 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.95bn | 111.00 | -- | 5.60 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Ideaya Biosciences Inc | 15.50m | -128.89m | 2.95bn | 124.00 | -- | 3.11 | -- | 190.05 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Biohaven Ltd | 0.00 | -517.18m | 2.95bn | 239.00 | -- | 9.07 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
Azenta Inc | 651.76m | -152.26m | 2.95bn | 3.40k | -- | 1.35 | -- | 4.53 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Arcellx Inc | 131.66m | -50.54m | 2.98bn | 130.00 | -- | 5.99 | -- | 22.67 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Twist Bioscience Corp | 277.49m | -192.14m | 3.03bn | 919.00 | -- | 5.40 | -- | 10.92 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Amicus Therapeutics, Inc. | 423.49m | -147.07m | 3.15bn | 517.00 | -- | 24.12 | -- | 7.45 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Denali Therapeutics Inc | 295.39m | -137.25m | 3.15bn | 375.00 | -- | 2.17 | -- | 10.68 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Mar 2024 | 5.83m | 12.51% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.69m | 5.77% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 2.49m | 5.34% |
RA Capital Management LPas of 20 May 2024 | 2.41m | 5.17% |
Federated Global Investment Management Corp.as of 31 Mar 2024 | 2.26m | 4.84% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.98m | 4.24% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.56m | 3.35% |
Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 1.53m | 3.28% |
Alyeska Investment Group LPas of 31 Mar 2024 | 1.30m | 2.79% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 1.28m | 2.75% |